Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NK cell engagers are a type of immunotherapy that can enhance the ability of NK cells to recognize and attack tumor cells. An NK cell engager with a tetravalent, bispecific structure works by binding to both the tumor-specific antigen (TSA) or tumor-associated antigen (TAA) on the surface of tumor cells and the CD16A receptor (also known as Fc gamma receptor IIIA) on the surface of NK cells. By forming a bridge between tumor cells and NK cells, NK cell engagers can promote the activation and killing of tumor cells by NK cells. This bivalent binding allows for specific targeting of tumor cells while activating the cytotoxic functions of NK cells, ultimately leading to the destruction of tumor cells.
The bivalent NK cell binding cell development service at Creative Biolabs aims to provide a platform for the development of NK cell engagers that harness the power of NK cells to target and destroy cancer cells. Our NK cell engagers are designed to selectively target TSA or TAA and CD16A. This targeted approach enhances the specificity and cytotoxic activity of NK cells against cancer cells while reducing off-target effects. The binding of NK cell engagers to CD16A activates the NK cells, triggering their cytotoxic functions and inducing the release of molecules that promote the destruction of the targeted tumor cells. Furthermore, these engagers have been designed to minimize NK cell fratricide, ensuring that the activated NK cells continue to target and destroy tumor cells effectively.
Our team of experts at Creative Biolabs is dedicated to developing custom bivalent NK cell binding cell solutions tailored to meet the unique needs of our clients. With our state-of-the-art technology and extensive experience in cell development, we design and optimize bivalent NK cell engagers that can effectively activate NK cells and enhance their cytotoxic activity against tumors. Our bivalent NK cell binding cell development service involves a comprehensive process that includes antigen screening, antibody design, affinity optimization, and functional validation to ensure the therapeutic efficacy of the engineered NK cells. Whether you are looking to develop novel NK cell engagers or optimize existing constructs, our service offers a tailored approach to meet your specific research needs.
Benefits of our bivalent NK cell engagers include:
Creative Biolabs, a leading provider of innovative solutions for cell therapy development, is at the forefront of advancing allogeneic CAR-NK therapy. With an extensive portfolio of services and expertise in cell engineering, our experts are dedicated to advancing allogeneic CAR-NK therapy and addressing critical challenges in cancer immunotherapy. Our bivalent NK cell binding cell development service offers a novel approach to improve the targeting and killing of cancer cells. contact us today to learn more about our bivalent NK cell binding cell development service and how we can support your research and development efforts in immuno-oncology.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
